医药魔方 / 最新资讯 / 正文

圈内身价最高的10位持股高管:Incyte独董NO.1,陈颂雄NO.10……

青瓦 青瓦 来源:医药魔方
2018-12-05
Incyte 榜单
原文

近日,GEN网站发布了“2018年亿万富翁TOP10”榜单。榜单显示:这10位富豪的累计身价为122.61亿美元,其中有4位企业高管的个人身价超过了10亿美元,排在首位的是Incyte制药首席独立董事Julian C. Baker,身价高达31.40亿美元。


GEN指出,在2017年榜单中,有5位身价超过10亿美元的高管,TOP10身价总额131.44亿。这很大程度上反映了二级市场股价在“过山车”,2016年股价暴跌,2017反弹,2018下跌。


与去年的榜单相比,今年的榜单中出现了两个新面孔,即Perrigo公司董事Jeffrey C. Smith和NantHealth/NantKwest公司CEO&董事长Patrick Soon-Shiong(陈颂雄),身价依次为7.95亿美元和4.91亿美元。


去年上榜、今年与榜单“失之交臂”的两位分别是Acetlion公司CEO Jean-Paul Clozel以及活跃的投资人William A. Ackman,后者在2017年卖掉了在Valeant制药的所有股份。


以下是入选“2018年亿万富翁TOP10”榜单的具体名单。


2018年亿万富翁TOP10(单位:亿美元)


GEN还对2019年的榜单做了预测,其推测2019年至少还将出现两个新面孔,即来自mRNA疗法新锐Moderna Therapeutics的董事长和CEO。


今年11月11日,Moderna向美国证券交易委员会(SEC)递交了IPO招股书,拟IPO募资5亿美元;11月28日,公司又将拟IPO募集金额上调至了6亿美元。


根据Moderna修改后的S-1/A文件,董事长Noubar B. Afeyan持有58,882,696股(19.5%),CEO Stéphane Bancel持有30,942,575股(10%)。


按照Moderna股票价格区间的高位值24美元/股计算,前者的股票总价值将达14.13亿美元,而后者将达到7.43亿美元,足以列入GEN任何一年亿万富翁榜单。即使按22美元/股的低位值计算,两位的股票总价值也将达到12.95亿美元和6.81亿美元,位列今年榜单的第4位和第8位。


不过正如GEN所评价道,随着二级市场股价的跌宕起伏,“身价”并不是稳定不变的,富豪的身价排名亦随着他们所持有的股票价格的变化而发生变化。但同时也从某个角度说明了,人家曾经踏过“亿万富翁”俱乐部。


机器翻译

Recently, GEN website released "2018 billionaire TOP10" list.The list shows that the 10 richest people have a cumulative value of 122.Of the $6.1 billion, four of the company's top executives were worth more than $1 billion, ranking first in Incyte Pharmaceuticals Chief Independent Director Julian C.Baker, worth as much as 31.$4 billion.

GEN points out that in the 2017 list, there are five executives worth more than $1 billion, and the total value of TOP10 is 131.4.4 billion.This largely reflects the secondary market share price in the "roller coaster", the stock price plummeted in 2016, 2017 rebound, 2018 down.

Compared to last year's list, two new faces appeared in this year's list, namely Jeffrey C, a director of Perrigo Corporation.Smith and Patrick Soon-Shiong (Chen Songxiong), Chairman of CEO &, NantHealth/NantKwest, in order of value.$9.5 billion and 4.$9.1 billion.

Last year on the list and this year on the list, two of them were Acetlion CEO Jean-Paul Clozel and active investor William A.Ackman, which sold all its shares in Valeant Pharmaceuticals in 2017.

The following is the specific list of the "2018 Billionaire TOP10" list.

2018 billionaire TOP10 (unit: US $)

GEN also made predictions on the 2019 list, which speculated that at least two new faces would emerge in 2019, namely from the board chairman and CEO of mRNA Therapy New Moderna Therapeutics.

On November 11 this year, Moderna submitted an IPO prospectus to the Securities and Exchange Commission of the United States (SEC) to raise 500 million U.S. dollars for IPO; on November 28, the company raised the amount of IPO raised to 600 million U.S. dollars.

According to Moderna's modified S-1/A document, Chairman Noubar B.Afeyan holds 58, 882, 696 shares (19.5%), CEO Stéphane Bancel holds 30, 942, 575 shares (10%).

According to the high value of the Moderna stock price range of $24/share, the total value of the former stock will reach 14.$1.3 billion, while the latter would reach 7.$4.3 billion, enough to be on the GEN list of billionaires in any given year.Even at a low value of $22 a share, the total value of the two shares will reach 12.$9.5 billion and 6.$8.1 billion, ranking fourth and eighth on this year's list.

However, as GEN has commented, with the ups and downs of the stock price in the secondary market, the "worth" is not stable, and the ranking of the wealthy people's worth also changes with the change of the stock price they hold.But at the same time, it also shows that people have been to the "billionaire" club.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号